fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

The European Ccommission approves Avzivi, a biosimilar referencing bevacizumab – Bio Thera Solutions

Written by | 9 Sep 2024 | Pharma News

The European Medicines Agency (EMA) has approved Avzivi (BAT 1706), a biosimilar referencing bevacizumab (Avastin), according to an announcement from Bio-Thera Solutions.

Avzivi is intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer and carcinoma of the cervix.

“The EMA approval of Avzivi is another significant accomplishment for Bio-Thera as it marks Bio-Thera’s second EMA-approved product” Shengfeng Li, chief executive officer at Bio-Thera Solutions, stated in a news release. “As our biosimilar pipeline continues to mature, we intend to seek more biosimilar approvals, expanding patient access to important therapies.”

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.